Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07507422 · ClinicalTrials.gov registry record
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
A clinical trial, sponsored by Medtronic.
- Recruiting
- Registry status
- 970
- Enrollment target
NCT07507422: Recruiting study, sponsored by Medtronic.
NCT07507422 is a clinical trial that is actively recruiting participants, run by Medtronic. The registered enrollment target is 970 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07507422 is actively recruiting participants, sponsored by Medtronic.
- RECRUITING
- Registry status
- 970 participants
- Enrollment target
Study Summary
The PERSIST study is being conducted within Medtronic's active post-market surveillance platform, the Product Surveillance Registry (PSR). The purpose of PERSIST is to generate long-term evidence for the Inceptiv™ Spinal Cord Stimulation therapy.
Primary Outcome
This outcome measures the percentage of implanted patients who demonstrate improvement in pain for the predominant pain condition being treated at 6 months following device activation, compared to baseline. Pain is assessed using the NPRS (with 0=no pain and 10=highest level of pain).
Interventions
- DEVICE Commercially available Inceptiv™ neurostimulation systems
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 970 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2034-01-11 |
What NCT07507422 shows while recruiting
NCT07507422 is an observational study that tracks outcomes without assigning an intervention. The registered 970 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Commercially available Inceptiv™ neurostimulation systems is the first listed.
NCT07507422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07507422 about?
NCT07507422 is a clinical study titled "Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy". The PERSIST study is being conducted within Medtronic's active post-market surveillance platform, the Product Surveillance Registry (PSR). The purpose of PERSIST is to generate long-term evidence for the Inceptiv™ Spinal Cord Stimulation therapy.
What is the current status of trial NCT07507422?
This trial is currently recruiting. The enrollment target is 970 participants. The study started on 2026-04-17. Estimated completion is 2034-01-11.
What interventions are being tested in trial NCT07507422?
The interventions under investigation include: Commercially available Inceptiv™ neurostimulation systems (DEVICE).
Who is sponsoring clinical trial NCT07507422?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI